Canada House Wellness Group Announces Issuance of Stock Options
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) is pleased to announce that the Company has agreed to grant 2,000,000 stock options to its Chief Executive Officer, Chris Churchill-Smith pursuant to its stock option plan.
Of the above options, 500,000 were issued as of June 27, 2018 at an exercise price of $0.21, vesting immediately and expiring June 27, 2023.
The remaining 1,500,000 options will be issued in three tranches of 500,000 on September 1, 2018, December 1, 2018 and March 1, 2019, respectively. Such options will be issued at an exercise price equal to the closing market price of the Company’s common shares as of the trading day prior to issuance, will vest immediately at the time of issuance and will have a term of five years.
Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visithttp://www.canadahouse.ca. orwww.sedar.com
For further information, please contact:
Boom Capital Markets
Steve Low
647-620-5101
steve@boomcapitalmarkets.com
Canada House Wellness Group, Inc.
Paul L. Hart
1-844-696-3349
phart@canadahouse.ca
Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
FSD Pharma (Nasdaq: HUGE) Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
